| |
|
|
|
|
|
 |
| |
|
»ó¾ÆÁ¦³î½ºÆ½ ZENOLSTICK[Beta-butoxyethyl nicotinate , Camphor , Diphenhydramine , Glycol Salicylate , Menthol , Methyl Salicylate]
|
|
ÀϹÝÀǾàǰ | ºñ±Þ¿©
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
[A35501261]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1g(2002.04.25)(ÇöÀç¾à°¡)
\0 ¿ø/1g(2002.04.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
[¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹é»ö, ¹ÌȲ»öÀÇ °íü·Î¼ ƯÀÌÇÑ ¹æÇâÀÌ ÀÖÀ½
[Á¦ÇüÁ¤º¸ È®ÀÎ]
|
| Æ÷À塤À¯Åë´ÜÀ§ |
40g |
| ¾à¸®ÀÛ¿ë |
[Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
±ÙÀ°Åë,Ÿ¹Ú, ¿°ÁÂ, °ßÅë, ¿äÅë, °ñÀýÅë, °üÀýÅë,½Å°æÅë, ·ù¸¶Æ¼Åë, ¹ú·¹¹°¸° µ¥, ÇǺΰ¡·Á¿òÁõ, 1µµ µ¿»ó.
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
[ÁÖ¼ººÐÄÚµå:342000CLN ¿¡ µû¸¥ ½É»çÁöħ¿¶÷]
1ÀÏ 1¡¼öȸ ȯºÎ¿¡ ¹Ù¸¥´Ù
|
| °æ°í |
´ÙÀ½ »ç¶÷Àº »ç¿ëÀü¿¡ ¾à»ç ¶Ç´Â ÀÇ»ç¿Í »óÀÇÇϽʽÿÀ.
- ¾àÀ̳ª ÈÀåǰ µî¿¡ ÀÇÇÑ ¾Ë·¹¸£±â Áõ»ó(¹ßÁø, ¹ßÀû, °¡·Á¿òÁõ, ¿Ì µî¿¡ ÀÇÇÑ ÇǺο° µî)ÀÌ ³ªÅ¸³ ÀûÀÌ ÀÖ´Â »ç¶÷
- ½ÀÀ±À̳ª Áø¹«¸§ÀÌ ½ÉÇÑ »ç¶÷
- ÀÇ»çÀÇ Ä¡·á¸¦ ¹Þ°í ÀÖ´Â »ç¶÷
|
| ±Ý±â |
30°³¿ùÀÌÇÏÀÇ À¯¾Æ
|
| ½ÅÁßÅõ¿© |
¼Ò¾Æ¿¡ Àû¿ë½Ã °æ·ÃÀ» À¯¹ßÇÒ ¼ö ÀÖÀ¸¹Ç·Î ½ÅÁßÈ÷ Åõ¿©ÇÒ °Í. |
| ÀϹÝÀû ÁÖÀÇ |
* ´ÙÀ½ »ç¶÷Àº »ç¿ëÀü¿¡ ¾à»ç ¶Ç´ÂÀÇ»ç¿Í »óÀÇÇÒ °Í
- ¾àÀ̳ª ÈÀåǰ µî¿¡ ÀÇÇÑ ¾Ë·¹¸£±â Áõ»ó(¹ßÁø, ¹ßÀû, °¡·Á¿òÁõ ¿Ì µî¿¡ ÀÇÇÑ ÇǺο°µîÀÌ ³ªÅ¸³ ÀûÀÌ ÀÖ´Â »ç¶÷
- ½ÀÀ±À̳ª Áø¹«¸§ÀÌ ½ÉÇÑ »ç¶÷
- ÀÇ»çÀÇ Ä¡·á¸¦ ¹Þ°í ÀÖ´Â »ç¶÷
* »ç¿ëÇÒ ¶§ ´ÙÀ½¿¡ ÁÖÀÇÇÒ °Í
- Á¤ÇØÁø ¿ë¹ý. ¿ë·®Àº Àß Áöų °Í
- ¼Ò¾Æ¿¡ »ç¿ëÇÒ °æ¿ì¿¡´Â °æ·ÃÀ» À¯¹ßÇÒ ¼ö ÀÖÀ¸¹Ç·Î ½ÅÁßÈ÷ Åõ¿©ÇÒ °Í
- ´«¿¡ µé¾î°¡Áö ¾Êµµ·Ï ÁÖÀÇ ÇÒ °Í. ¸¸ÀÏ ´«¿¡ µé¾î°£ °æ¿ì¿¡´Â ¹°·Î ¾ÄÀ» °Í. Áõ»óÀÌ ½ÉÇÑ °æ¿ì¿¡´Â ¾È°úÀÇ¿¡°Ô Áø·á¸¦ ¹Þ´Â´Ù.
- ÀÌ ¾àÀº ¿Ü¿ëÀ¸·Î¸¸ »ç¿ëÇÏ°í ³»º¹ÇÏÁö ¸» °Í
* »ç¿ëÁß ¶Ç´Â »ç¿ëÈÄ¿¡´Â ´ÙÀ½¿¡ ÁÖÀÇ ÇÒ °Í
- ÀÌ ¾àÀÇ »ç¿ëÀ¸·Î ÀÎÇØ ¹ßÁø, ¹ßÀû, °¡·Á¿ò µîÀÇ Áõ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â »ç¿ëÀ» ÁßÁöÇÏ°í ¾à»ç ¶Ç´Â ÀÇ»ç¿Í »óÀÇ ÇÒ °Í
- ¼öÀϰ£ »ç¿ëÇÏ¿©µµ Áõ»óÀÌ °³¼±µÇÁö ¾ÊÀ» °æ¿ì¿¡´Â »ç¿ëÀ» ÁßÁöÇÏ°í ¾à»ç ¶Ç´Â ÀÇ»ç¿Í »óÀÇÇÒ °Í
|
| Àû¿ë»óÀÇ ÁÖÀÇ |
* ´ÙÀ½ÀÇ ºÎÀ§¿¡´Â »ç¿ëÇÏÁö ¸» °Í
´«ÁÖÀ§, Á¡¸·µî, ½ÀÀ±, ¿Ì µî¿¡ ÀÇÇÑ ÇǺο°, »óóºÎÀ§ |
| º¸°ü ¹× Ãë±Þ»óÀÇ ÁÖÀÇ |
- ¼Ò¾ÆÀÇ ¼ÕÀÌ ´êÁö ¾Ê´Â °÷¿¡ º¸Á¸ÇÒ °Í
- Á÷»çÀϱ¤À» ÇÇÇÏ°í µÉ ¼ö Àִ´ë·Î ½À±â°¡ Àû°í ¼´ÃÇÑ °÷¿¡ ¹ÐÀüÇÏ¿© º¸Á¸ÇÒ °Í
- ¿À¿ëÀ» ¸·°í ǰÁúÀ» À¯ÁöÇϱâ À§ÇØ ´Ù¸¥ ¿ë±â¿¡ ³ÖÁö ¸» °Í
|
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Bµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| µ¶¼ºÁ¤º¸ |
Camphor¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Diphenhydramine¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do |
| Mechanism of Action |
Diphenhydramine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Diphenhydramine competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding.
Menthol¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Menthol is classified as a calcium channel blocker. Calcium channel blockers are a class of drugs with effects on many excitable cells of the body, like the muscle of the heart, smooth muscles of the vessels or neuron cells. Calcium channel blockers work by blocking voltage-sensitive calcium channels in the heart and in the blood vessels. This prevents calcium levels from increasing as much in the cells when stimulated, leading to less contraction.
|
| Pharmacology |
Diphenhydramine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Diphenhydramine is an antihistamine of the ethanolamine class. Ethanolamine antihistamines have significant antimuscarinic activity and produce marked sedation in most patients. In addition to the usual allergic symptoms, the drug also treats irritant cough and nausea, vomiting, and vertigo associated with motion sickness. It also is used commonly to treat drug-induced extrapyramidal symptoms as well as to treat mild cases of Parkinson's disease. Rather than preventing the release of histamine, as do cromolyn and nedocromil, diphenhydramine competes with free histamine for binding at HA-receptor sites. Diphenhydramine competitively antagonizes the effects of histamine on HA-receptors in the GI tract, uterus, large blood vessels, and bronchial muscle. Ethanolamine derivatives have greater anticholinergic activity than do other antihistamines, which probably accounts for the antidyskinetic action of diphenhydramine. This anticholinergic action appears to be due to a central antimuscarinic effect, which also may be responsible for its antiemetic effects, although the exact mechanism is unknown.
Menthol¿¡ ´ëÇÑ Pharmacology Á¤º¸ Menthol is a covalent organic compound made synthetically or obtained from peppermint or other mint oils. Menthol's ability to chemically trigger cold-sensitive receptors in the skin is responsible for the well known cooling sensation that it provokes when inhalated, eaten, or applied to the skin. It should be noted that menthol does not cause an actual drop in temperature.
|
| Metabolism |
Diphenhydramine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 2D6 (CYP2D6)Cytochrome P450 3A4 (CYP3A4)
|
| Protein Binding |
Diphenhydramine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 98 to 99%
Menthol¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Not Available
|
| Half-life |
Diphenhydramine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 1-4 hours
Menthol¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available
|
| Absorption |
Diphenhydramine¿¡ ´ëÇÑ Absorption Á¤º¸ Quickly absorbed with maximum activity occurring in approximately one hour.
Menthol¿¡ ´ëÇÑ Absorption Á¤º¸ Not Available
|
| Pharmacokinetics |
MentholÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ¼Ò½Ç : Èí¼öµÈ ¾à¹°Àº glucuronide Æ÷ÇÕü·Î¼ ¼Òº¯ ¹× ´ãÁóÀ» ÅëÇØ ¹è¼³µÈ´Ù.
Beta-butoxyethyl nicotinateÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ¿©·¯ Á¦Çü Áß¿¡¼ Á¡ºñÁ¦°¡ Èí¿¬ ÈÄ ³ªÅ¸³ª´Â Ç÷Áß ½Ã°£-³óµµ °î¼±ÀÇ ¾ç»ó°ú °¡Àå À¯»çÇÏ´Ù.
- ÀÛ¿ëÁö¼Ó½Ã°£ : °æÇÇÁ¦Á¦ : 24½Ã°£
- Èí¼ö : °æÇÇÁ¦Á¦ : ´À¸²
- ´ë»ç : °£´ë»ç. ÁÖ·Î 1/5ÀÇ È°¼ºÀ» Áö´Ñ cotinineÀ¸·Î ´ë»çµÊ.
- ¹Ý°¨±â : 4½Ã°£
- Ç÷ÁßÃÖ°í³óµµ µµ´Þ½Ã°£ : °æÇÇÁ¦Á¦ : 8-9 ½Ã°£
- ¼Ò½Ç : ½Å¹è¼³. ½ÅŬ¸®¾î·±½º´Â pH-ÀÇÁ¸Àû.
Methyl SalicylateÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- Èí¼ö :
- À§Àå°üÀ¸·ÎºÎÅÍ Àß Èí¼öµÈ´Ù.
- ¹þ°ÜÁø ÇǺθ¦ ÅëÇØ¼µµ Èí¼öµÉ ¼ö ÀÖ´Ù.
DiphenhydramineÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ÃÖ°í ÁøÁ¤ È¿°ú : 1-3 ½Ã°£
- ÀÛ¿ëÁö¼Ó½Ã°£ : 4-7 ½Ã°£
- Èí¼ö : ÃÊȸÅë°úÈ¿°ú°¡ ÀÖ¾î¼ 40 - 60 % Á¤µµ°¡ Àü½Å¼øÈ¯À¸·Î µé¾î°¨
- ´ë»ç : ´ëºÎºÐ °£´ë»ç, ÀϺδ Æó¿Í ½ÅÀå¿¡¼µµ ´ë»ç
- ´Ü¹é°áÇÕ : 78%
- ÃÖ°íÇ÷Áß³óµµ µµ´Þ½Ã°£ : 2-4 ½Ã°£
|
| Biotransformation |
Diphenhydramine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic and renal
|
| Toxicity |
Diphenhydramine¿¡ ´ëÇÑ Toxicity Á¤º¸ LD50=500 mg/kg (orally in rats). Considerable overdosage can lead to myocardial infarction (heart attack), serious ventricular dysrhythmias, coma and death.
Menthol¿¡ ´ëÇÑ Toxicity Á¤º¸ Menthol, DL: ORAL (LD50): Acute: 2900 mg/kg [Rat], 3100 mg/kg [Mouse]. DERMAL (LD50): Acute: 5001 mg/kg [Rabbit].
|
| Drug Interactions |
Diphenhydramine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Atomoxetine The CYP2D6 inhibitor could increases the effect and toxicity of atomoxetineDonepezil Possible antagonism of actionGalantamine Possible antagonism of actionMesoridazine Increased risk of cardiotoxicity and arrhythmiasRivastigmine Possible antagonism of actionThioridazine Increased risk of cardiotoxicity and arrhythmias
Menthol¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Food Interaction |
Diphenhydramine¿¡ ´ëÇÑ Food Interaction Á¤º¸ Avoid alcohol.Take with food.
|
| Drug Target |
[Drug Target]
|
| Description |
Camphor¿¡ ´ëÇÑ Description Á¤º¸ A bicyclic monoterpene ketone found widely in plants, especially cinnamomum camphora. It is used topically as a skin antipruritic and as an anti-infective agent. [PubChem]
Diphenhydramine¿¡ ´ëÇÑ Description Á¤º¸ A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects.
Menthol¿¡ ´ëÇÑ Description Á¤º¸ Menthol is a covalent organic compound made synthetically or obtained from peppermint or other mint oils. It is a waxy, crystalline substance, clear or white in color, which is solid at room temperature and melts slightly above. The main form of menthol occurring in nature is (-)-menthol, which is assigned the (1R,2S,5R) configuration. Menthol has local anesthetic and counterirritant qualities, and it is widely used to relieve minor throat irritation.
|
| Dosage Form |
Diphenhydramine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule OralCream TopicalElixir OralLiquid IntramuscularLiquid IntravenousLiquid OralLozenge OralStrip OralSyrup OralTablet OralTablet, chewable Oral
Menthol¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Cream TopicalGel TopicalLiquid NasalLiquid OralLiquid TopicalLozenge OralOintment TopicalPatch TopicalPowder TopicalSolution / drops OralSpray Topical
|
| Drug Category |
Camphor¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Infective Agents, Local
Diphenhydramine¿¡ ´ëÇÑ Drug_Category Á¤º¸ AnestheticsAnesthetics, LocalAnti-Allergic AgentsAntidyskineticsAntiemeticsAntiparkinson AgentsAntipruriticsAntitussivesEthanolamine DerivativesHistamine H1 AntagonistsHypnotics and Sedatives
Menthol¿¡ ´ëÇÑ Drug_Category Á¤º¸ Antipruritics
|
| Smiles String Canonical |
Camphor¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC1(C)C2CCC1(C)C(=O)C2
Diphenhydramine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
Menthol¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC(C)C1CCC(C)CC1O
|
| Smiles String Isomeric |
Camphor¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CC1(C)[C@H]2CC[C@]1(C)C(=O)C2
Diphenhydramine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
Menthol¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
|
| InChI Identifier |
Camphor¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C10H16O/c1-9(2)7-4-5-10(9,3)8(11)6-7/h7H,4-6H2,1-3H3
Diphenhydramine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C17H21NO/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16/h3-12,17H,13-14H2,1-2H3
Menthol¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C10H20O/c1-7(2)9-5-4-8(3)6-10(9)11/h7-11H,4-6H2,1-3H3/t8-,9+,10-/m1/s1
|
| Chemical IUPAC Name |
Camphor¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 1,7,7-trimethylbicyclo[2.2.1]heptan-2-one
Diphenhydramine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 2-[di(phenyl)methoxy]-N,N-dimethylethanamine
Menthol¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (1R,2S,5R)-5-methyl-2-propan-2-ylcyclohexan-1-ol
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2019-01-07
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|
|
|